A mutant Shiga-like toxin lie bound to its receptor Gb3: Structure of a group II Shiga-like toxin with altered binding specificity

Structure

Volumn 8, Issue 3, 2000, Pages 253-264

  Ling, Hong ^a   Pannu, Navraj S ^b   Boodhoo, Amechand ^a   Armstrong, Glen D ^a   Clark, Clifford G ^c   Brunton, James L ^d,e   Read, Randy J ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Bur Microbiol Lab Ctr Dis C   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bacterial toxins; Glycolipid; Mutagenesis; Protein carbohydrate recognition; Receptor binding

Indexed keywords

RECEPTOR; VEROTOXIN;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; ESCHERICHIA COLI; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR BINDING;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; NEGIBACTERIA; SUS SCROFA;

EID: 0034653374     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00103-9     Document Type: Article

References (72)

1. Riley L.W., Cohen M.L.et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N. Engl. J. Med. 308:1983;681-685.
2. Karmali M.A., Steele B.T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1:1983;619-620.
3. O'Brien A.D., Lively T.A., Chang T.W., Gorbach S.L. Purification of Shigella dysenteriae 1 (Shiga)-like toxin from Escherichia coli O157:H7 strain associated with haemorrhagic colitis. Lancet. 2:1983;573.
4. Armstrong G.L., Hollingsworth J., Morris J.G. Jr. Emerging foodborne pathogens: Escherichia coli O157:H7 as a model of entry of a new pathogen into the food supply of the developed world. Epidemiol. Rev. 18:1996;29-51.
5. Mahon B.E., Griffin P.M., Mead P.S., Tauxe R.V. Hemolytic uremic syndrome surveillance to monitor trends in infection with Escherichia coli O157:H7 and other Shiga toxin-producing E. coli. Emerg. Infect. Dis. 3:1997;409-412.
6. Qadri S.M., Kayali S. Enterohemorrhagic Escherichia coli. A dangerous food-borne pathogen. Postgrad. Med. 103:1998;179-180. 185-187.
7. Cimolai N., Carter J.E., Morrison B.J., Anderson J.D. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syndrome. J. Pediatr. 116:1990;589-592.
8. Proulx F., Turgeon J.P., Delage G., Lafleur L., Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J. Pediatr. 121:1992;299-303.
9. Weinstein D.L., Jackson M.P., Perera L.P., Holmes R.K., O'Brien A.D. In vivo formation of hybrid toxins comprising Shiga toxin and the Shiga-like toxins and the role of the B subunit in localization and cytotoxic activity. Infect. Immun. 57:1989;3743-3750.
10. Lingwood C.A. Verotoxins and their glycolipid receptors. Adv. Lipid Res. 25:1993;189-211.
11. Hazes B., Read R.J. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated degradation pathway to enter cells. Biochemistry. 36:1997;11051-11054.
12. Endo Y., Tsurugi K., Yutsudo T., Takeda Y., Ogasawara K., Igarashi K. Site of action of a Verotoxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes: RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171:1988;45-50.
13. Jacewicz M., Clausen H., Nudelman E., Donohue-Rolfe A., Keusch G.T. Pathogenesis of Shigella diarrhea. XI. Isolation of a Shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J. Exp. Med. 163:1986;1391-1404.
14. Lindberg A.A., Brown J.E., Strömberg N., Westling-Ryd M., Schultz J.E., Karlsson K.A. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J. Biol. Chem. 262:1987;1779-1785.
15. Lingwood C.A., Karmali M.et al. Glycolipid binding of purified and recombinant Escherichia coli-produced verotoxin in vitro. J. Biol. Chem. 262:1987;8834-8839.
16. Waddell T., Head S., Petric M., Cohen A., Lingwood C. Globotriosyl ceramide is specifically recognized by Escherichia coli verocytotoxin 2. Biochem. Biophys. Res. Commun. 152:1988;674-679.
17. Cohen A., Hannigan G.E., Williams B.R., Lingwood C.A. Roles of globotriosyl- and galabiosylceramide in Verotoxin binding and high affinity interferon receptor. J. Biol. Chem. 262:1987;17088-17091.
18. Tesh V.L., Samuel J.E., Perera L.P., Sharefkin J.B., O'Brien A.D. Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells. J. Infect. Dis. 164:1991;344-352.
19. Obrig T.G., Louise C.B., Lingwood C.A., Boyd B., Barley-Maloney L., Daniel T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. J. Biol. Chem. 268:1993;15484-15488.
20. Konowalchuk J., Speirs J.I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect. Immun. 18:1977;775-779.
21. O'Brien A.D., LaVeck G.D. Purification and characterization of a Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect. Immun. 40:1983;675-683.
22. Brunton J.L. The Shiga toxin family: molecular nature and possible role in disease. Iglewski B., Clark V. The Bacteria, Vol XI, Molecular Basis of Bacterial Pathogenesis. 1990;377-398 Academic Press, New York, NY.
23. O'Brien A.D., Newland J.W., Miller S.F., Holmes R.K., Smith H.W., Formal S.B. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science. 226:1984;694-696.
24. Karmali M.A., Petric M., Lim C., Fleming P.C., Arbus G.S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151:1985;775-782.
25. MacLeod D.L., Gyles C.L., Wilcock B.P. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet. Pathol. 28:1991;66-73.
26. Tesh V.L., Samuel J.E.et al. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61:1993;3392-3402.
27. Wadolkowski E.A., Sung L.M., Burris J.A., Samuel J.E., O'Brien A.D. Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin II. Infect. Immun. 58:1990;3959-3965.
28. Louise C.B., Obrig T.G. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J. Infect. Dis. 172:1995;1397-1401.
29. Head S.C., Karmali M.A., Lingwood C.A. Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of A subunit function. J. Biol. Chem. 266:1991;3617-3621.
30. Armstrong G.D., Fodor E., Vanmaele R. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences. J. Infect. Dis. 164:1991;1160-1167.
31. Armstrong G.D., McLaine P.N.et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J. Infect. Dis. 171:1995;1042-1045.
32. Armstrong G.D., McLaine P.D., Roew P.C. Clinical trials of Synsorb-Pk in preventing hemolytic-uremic syndrome. Kaper J.B., O'Brien A.D. Escherichia coli O157:H7 and Other Shiga toxin-Producing E. coli Strains. 1998;374-384 ASM Press, Washington, DC.
33. De Grandis S., Law H., Brunton J., Gyles C., Lingwood C.A. Globotetraosylceramide is recognized by the pig edema disease toxin. J. Biol. Chem. 264:1989;12520-12525.
34. Keusch G.T., Jacewicz M., Acheson D.W.K., Donohue-Rolfe A., Kane A.V., McCluer R.H. Globotriaosylceramide, Gb3, is an alternative functional receptor for Shiga-like toxin 2e. Infect. Immun. 63:1995;1138-1141.
35. Tyrrell G.J., Ramotar K., Toye B., Boyd B., Lingwood C.A., Brunton J.L. Alteration of the carbohydrate binding specificity of verotoxins from Galα1-4Gal to GalNAcβ1-3Galα1-4Gal and vice versa by site-directed mutagenesis of the binding subunit. Proc. Natl Acad. Sci. USA. 89:1992;524-528.
36. Boyd B., Tyrrell G., Maloney M., Gyles C., Brunton J., Lingwood C. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targeting and results in a verotoxin 1-like disease in pigs. J. Exp. Med. 177:1993;1745-1753.
37. 3. Biochemistry. 37:1998;1777-1788.
38. Acheson D.W., Keusch G.T.et al. Expression and purification of Shiga-like toxin II B subunits. Infect. Immun. 63:1995;301-308.
39. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl. Crystallogr. 26:1993;283-291.
40. Stein P.E., Boodhoo A., Tyrrell G.J., Brunton J.L., Read R.J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature. 355:1992;748-750.
41. Fraser M.E, Chernaia M.M, Kozlov Y.V., James M.N.G. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1:1994;59-64.
42. Read R.J. Improved Fourier coefficents for maps using phases from partial structures with errors. Acta Crystallogr. A. 42:1986;140-149.
43. Read R.J. Model phases: probabilities and bias. Methods Enzymol. 227:1997;110-128.
44. Murzin A.G. OB(oligonucleotide/oligosaccharide binding)-fold: common structural and functional solution for non-homologous sequences. EMBO J. 12:1993;861-867.
45. Shimizu H., Field R.A., Homans S.W., Donohue-Rolfe A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry. 37:1998;11078-11082.
46. Lindgren S.W., Samuel J.E., Schmitt C.K., O'Brien A.D. The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by Vero cell cytotoxicity but not by mouse lethality. Infect. Immun. 62:1994;623-631.
47. Perera L.P., Samuel J.E., Holmes R.K., O'Brien A.D. Identification of three amino acid residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity. J. Bacteriol. 173:1991;1151-1160.
48. Nyholm P-G., Magnusson G., Zheng Z., Norel R., Binnington-Boyd B., Lingwood C.A. Two distinct binding sites for globotriaosyl ceramide on verotoxins: identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins. Chem. Biol. 3:1996;263-275.
49. 3 on verotoxin 1 using fluorescence analysis. Biochemistry. 38:1999;7177-7184.
50. Cummings M.D., Ling H., Armstrong G.D., Brunton J.L., Read R.J. Modeling the carbohydrate-binding specificity of pig edema toxin. Biochemistry. 37:1998;1789-1799.
51. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd:1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
52. Gyles C.L., De Grandis S.A., MacKenzie C., Brunton J.L. Cloning and nucleotide sequence analysis of the genes determining verocytotoxin production in a porcine edema disease isolate of Escherichia coli. Microb. Pathog. 5:1988;419-426.
53. Amann E., Brosius J., Ptashne M. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli. Gene. 25:1983;167-178.
54. Ramotar K., Boyd B., Tyrrell G., Gariepy J., Lingwood C., Brunton J. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. Biochem. J. 272:1990;805-811.
55. Howard A.J., Gilliland G.L., Finzel B.C., Poulos T.L., Ohlendorf D.H., Salemme F.R. The use of an imaging proportional counter in macromolecular crystallography. J. Appl. Crystallogr. 20:1987;383-387.
56. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A. 50:1994;157-163.
57. Fujinaga M., Read R.J. Experiences with a new translation function program. J. Appl. Crystallogr. 20:1987;517-521.
58. Brünger A.T. X-PLOR, a SYstem for X-ray CRystallography and NMR, Version 3.1. 1992;Yale University Press, New Haven, CT.
59. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of error in these models. Acta Crystallogr. A. 47:1991;110-119.
60. Vellieux F.M.D.A.P., Hunt J.F., Roy S., Read R.J. DEMON/ANGEL: a suite of programs to carry out density modification. J. Appl. Crystallogr. 28:1995;347-351.
61. Brünger A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992;472-475.
62. Jiang J.S., Brünger A.T. Protein hydration observed by X-ray diffraction. Solvation properties of penicillopepsin and neuraminidase crystal structures. J. Mol. Biol. 243:1994;100-115.
63. Pannu N.S., Read R.J. Improved structure refinement through maximum likelihood. Acta Crystallogr. A. 52:1996;659-668.
64. Kleywegt G.J., Brünger A.T. Checking your imagination: applications of the free R value. Structure. 4:1996;897-904.
65. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 33:1968;491-497.
66. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D. 50:1994;760-763.
67. Brünger A.T., Warren G.L.et al. Crystallography and NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. D. 54:1998;905-921.
68. McRee D.E. XtalView/Xfit - a versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:1999;156-165.
69. Rice L.M., Brünger A.T. Torsion angle dynamics: reduced variable conformational sampling enhances crystallographic structure refinement. Proteins. 19:1994;277-290.
70. Lamzin V.S., Wilson K.S. Automated refinement of protein models. Acta Crystallogr. D. 49:1993;129-147.
71. Barton G.J. ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng. 6:1993;37-40.
72. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:1991;946-950.